Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

Look in more depth at the results. Different

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Lorcan458 Member Profile
 
Followed By 0
Posts 55
Boards Moderated 0
Alias Born 09/14/16
160x600 placeholder
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Rese... PR Newswire (US) - 5/27/2020 7:25:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/8/2020 12:05:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 6:32:09 AM
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update GlobeNewswire Inc. - 5/7/2020 6:30:10 AM
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European U... GlobeNewswire Inc. - 5/7/2020 1:00:10 AM
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology GlobeNewswire Inc. - 5/4/2020 3:30:10 AM
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update GlobeNewswire Inc. - 4/29/2020 6:00:10 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/8/2020 6:03:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:17:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:16:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:15:05 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:14:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 6:12:49 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/7/2020 6:12:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/3/2020 5:01:27 PM
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority GlobeNewswire Inc. - 4/3/2020 6:59:09 AM
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer GlobeNewswire Inc. - 4/1/2020 9:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 7:52:11 AM
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors GlobeNewswire Inc. - 3/31/2020 4:00:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/18/2020 6:02:58 AM
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 GlobeNewswire Inc. - 3/16/2020 3:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/13/2020 5:02:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/13/2020 5:02:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/6/2020 5:07:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/6/2020 5:05:46 PM
Lorcan458   Wednesday, 01/17/18 10:51:54 AM
Re: TopelRoad post# 2416
Post # of 2685 
Look in more depth at the results. Different markers diminish at different rates. You're best bet would be to ask the most knowledgable medicial or scientific person you know to look at the data. We amatuers are guessing. Guessing is not the best investment strategy.

Phase 2 was meant to show safety. Although there were measurable medical improvements, a single dose is not how the treatment will be administered when looking for efficacy. That's happening right now in phase 3. If more people get up and walk away from wheelchairs, we've made a great investment. If there is a previously unknown safety issue, severe enough side effect or a lack of efficacy, we made an economically bad investment, but at least it was an investment to bring hope to those suffering with ALS. I'd rather lose money on this than on something like bitcoin.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist